Last updated on August 2018

Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment


Brief description of study

Hepatic impairment PK study

Detailed Study Description

This is a non randomized, open label, single dose, parallel cohort, multisite study to investigate the effect of varying degrees of hepatic impairment on the plasma pharmacokinetics (total and unbound) of PF-05221304 after a single oral dose administered in the fed state.

Clinical Study Identifier: NCT03309202

Contact Investigators or Research Sites near you

Start Over

Pfizer CT.gov Call Center

Nemocnice Na Bulovce
Praha 8, Czechia
0.21miles

Pfizer CT.gov Call Center

Pharmaceutical Research Associates CZ, s.r.o.
Praha 7, Czechia
1.96miles